Number of the records: 1
２’３’－環状ジヌクレオチドおよびそのプロドラッ
- 1.
SYSNO ASEP 0580598 Document Type P - Patent R&D Document Type Patent or other outcome protected by special legislation Title ２’３’－環状ジヌクレオチドおよびそのプロドラッ Title 2'3'-cyclic dinucleotides and prodrugs thereof Author(s) Birkuš, Gabriel (UOCHB-X) ORCID
Páv, Ondřej (UOCHB-X) RID, ORCID
Kostov, Ondřej (UOCHB-X) RID
Břehová, Petra (UOCHB-X) RID, ORCID
Kaiser, Martin Maxmilian (UOCHB-X) RID, ORCID
Šimák, Ondřej (UOCHB-X) RIDYear of issue 2023 Possible third party use of the result A - Pro využití výsledku jiným subjektem je vždy nutné nabytí licence Royalty requested A - Poskytovatel licence požaduje licenční poplatek Patent no. or utility model no. or industrial design no. JP7350871 Date of the patent acceptance 26.09.2023 Name of the patent owner Ústav organické chemie a biochemie AV ČR, v. v. i Code of the issuer name JP001 - Japan Patent Office (JPO) Tokyo Current use A - Pouze udělený (dosud nevyužívaný) patent nebo patent využívaný jeho vlastníkem Territorial Protection NEU - národní patent v zemi mimo EU
PCT - mezinárodní patentová ochrana dle Smlouvy o patentové spolupráciLanguage jpn - Japanese Keywords STING ; cyclic dinucleotide ; oncology OECD category Medicinal chemistry R&D Projects EF16_019/0000729 GA MŠMT - Ministry of Education, Youth and Sports (MEYS) Institutional support UOCHB-X - RVO:61388963 Annotation 本開示は、一般式（Ｉ）の２’３’環状ホスホネートジヌクレオチド、それらの薬学的に許容可能な塩、それらの薬学的組成物、ならびに前記物質および他の医薬品または医薬の組み合わせに関する。本開示はまた、ＳＴＩＮＧタンパク質調節によって改変可能な疾患または状態（例えば、癌またはウイルス、アレルギー性および炎症性疾患）の治療または予防のための上記化合物の使用に関する。さらに、これらの物質は、ワクチンにおけるアジュバントとして使用され得る。【化１
Description in English The present disclosure relates to 2'3' cyclic phosphonate dinucleotides of Formula (I), their pharmaceutically acceptable salts, their pharmaceutical composition and combinations of said substances and other medicaments or pharmaceuticals. The disclosure also relates to the use of said compounds for the treatment or prevention of diseases or conditions modifiable by STING protein modulation, such as cancer or viral, allergic and inflammatory diseases. In addition, these substances can be used as adjuvants in vaccines. Workplace Institute of Organic Chemistry and Biochemistry Contact asep@uochb.cas.cz ; Kateřina Šperková, Tel.: 232 002 584 ; Jana Procházková, Tel.: 220 183 418 Year of Publishing 2024 Electronic address https://worldwide.espacenet.com/patent/search/family/069845482/publication/JP7350871B2?q=JP7350871B2
Number of the records: 1